Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Computer alert boosts aspirin use in High-Risk pregnancies

NCT ID NCT05802940

Knowledge-focused Sponsor: Geisinger Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tested whether a pop-up alert in electronic health records could increase doctors' recommendations for low-dose aspirin in pregnant women at high risk for preeclampsia. Over 800 women were included, and the alert was shown during prenatal visits. The goal was to see if the alert improved aspirin recommendations compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this alert system could become a standard tool to ensure more high-risk pregnant women receive aspirin to prevent preeclampsia.
What could go wrong
This is a completed study testing a behavioral intervention, not a new drug. The alert may not work in all healthcare settings or may cause alert fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

830 people

The number who actually took part.

Started

Jun 2023

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Receiving prenatal care within Geisinger * Initial prenatal visit prior to 28 weeks gestation * Determined to be high risk for preeclampsia based on the modified United States Preventive Services Task Force and American College of Obstetrics and Gynecology criteria (at least 1 high risk factor) Exclusion Criteria: * Not pregnant * No prenatal visit prior to 28 weeks gestation * Maternal-Fetal Medicine only visits * Not meeting the modified USPSTF high-risk criteria * Contraindication to aspirin, including allergy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aspirin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Behavior preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aspirin Clinical decision support systems Economics, behavioral Preeclampsia

Contacts and locations

Locations

  • Geisinger Medical Center

    Danville, Pennsylvania, 17822, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.